CA2893402A1 - Compositions therapeutiques renfermant des composes chromanyles ou des variantes et analogues de ceux-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux - Google Patents

Compositions therapeutiques renfermant des composes chromanyles ou des variantes et analogues de ceux-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux Download PDF

Info

Publication number
CA2893402A1
CA2893402A1 CA2893402A CA2893402A CA2893402A1 CA 2893402 A1 CA2893402 A1 CA 2893402A1 CA 2893402 A CA2893402 A CA 2893402A CA 2893402 A CA2893402 A CA 2893402A CA 2893402 A1 CA2893402 A1 CA 2893402A1
Authority
CA
Canada
Prior art keywords
deficiency
syndrome
mitochondrial
levels
myopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2893402A
Other languages
English (en)
Inventor
D. Travis Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Corp
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Priority to CA2893402A priority Critical patent/CA2893402A1/fr
Publication of CA2893402A1 publication Critical patent/CA2893402A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2893402A 2015-05-26 2015-05-26 Compositions therapeutiques renfermant des composes chromanyles ou des variantes et analogues de ceux-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux Abandoned CA2893402A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2893402A CA2893402A1 (fr) 2015-05-26 2015-05-26 Compositions therapeutiques renfermant des composes chromanyles ou des variantes et analogues de ceux-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2893402A CA2893402A1 (fr) 2015-05-26 2015-05-26 Compositions therapeutiques renfermant des composes chromanyles ou des variantes et analogues de ceux-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux

Publications (1)

Publication Number Publication Date
CA2893402A1 true CA2893402A1 (fr) 2016-11-26

Family

ID=57357026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2893402A Abandoned CA2893402A1 (fr) 2015-05-26 2015-05-26 Compositions therapeutiques renfermant des composes chromanyles ou des variantes et analogues de ceux-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux

Country Status (1)

Country Link
CA (1) CA2893402A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917215A (zh) * 2022-04-27 2022-08-19 中国科学院生物物理研究所 活性化合物预防或治疗卵巢功能障碍性疾病的用途
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN114917215A (zh) * 2022-04-27 2022-08-19 中国科学院生物物理研究所 活性化合物预防或治疗卵巢功能障碍性疾病的用途
CN114917215B (zh) * 2022-04-27 2024-01-23 中国科学院生物物理研究所 活性化合物预防或治疗卵巢功能障碍性疾病的用途

Similar Documents

Publication Publication Date Title
CA2984407A1 (fr) Compositions therapeutiques renfermant un triterpenoide et utilisations associees en vue de traiter et prevenir les maladies mitochondriales
Lu et al. CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation
CA2917336A1 (fr) Compositions therapeutiques renfermant des derives de catecol et ses utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
Ma et al. BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16
CA2973885A1 (fr) Compositions therapeutiques renfermant des composes de creatine ciblant les mitochondries et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
CN115814053A (zh) 氨基酸组合物及肝疾病的治疗方法
Hui et al. Inhibition of the Keap1-Nrf2 protein-protein interaction protects retinal cells and ameliorates retinal ischemia-reperfusion injury
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
CA2881746A1 (fr) Compositions therapeutiques renfermant des peptides inhibiteurs de fission mitochondriale, des variants de ceux-ci, et methodes d'utilisation associees en vue de traiter et prevenir les maladies et troubles mitochondriaux
Kourakis et al. Targeting Nrf2 for the treatment of Duchenne muscular dystrophy
Sun et al. ROS production and mitochondrial dysfunction driven by PU. 1-regulated NOX4-p22phox activation in Aβ-induced retinal pigment epithelial cell injury
CA2893245A1 (fr) Compositions therapeutiques renfermant du bpm 31510, des variantes et analogues de celui-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
CA2973891A1 (fr) Compositions therapeutiques renfermant des composes de creatine modifies et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
US20190076429A1 (en) Methods for treating friedreich's ataxia with etravirine
Yang et al. HJ22, a Novel derivative of piperine, Attenuates ibotenic acid-induced cognitive impairment, oxidativestress, apoptosis and inflammation via inhibiting the protein-protein interaction of Keap1-Nrf2
JP7053692B2 (ja) 神経変性障害の治療又は予防のための細胞内Ｎｉｘ介在性マイトファジーを増大させる剤及び方法並びにキット
CA2920246A1 (fr) Compositions therapeutiques renfermant des derives de chromane et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
US20190336519A1 (en) Application of albiflorin as indoleamine 2,3-dioxygenase (ido) inhibitor
CA2893402A1 (fr) Compositions therapeutiques renfermant des composes chromanyles ou des variantes et analogues de ceux-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
Wu et al. Isoginkgetin, a bioactive constituent from Ginkgo Biloba, protects against obesity-induced cardiomyopathy via enhancing Nrf2/ARE signaling
Zhang et al. FTZ protects against cardiac hypertrophy and oxidative injury via microRNA-214/SIRT3 signaling pathway
CA2894005A1 (fr) Compositions therapeutiques renfermant des composes skq et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
CA2920272A1 (fr) Compositions therapeutiques renfermant de la phenazine-3-one et des derives de phenothiazine-3-one et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
Wang et al. Recent progress and applications of small molecule inhibitors of Keap1–Nrf2 axis for neurodegenerative diseases
Cai et al. Coniferaldehyde prevents articular cartilage destruction in a murine model via Nrf2/HO‑1 pathway

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190528

FZDE Discontinued

Effective date: 20190528